Tradegate
23.12.24
09:31 Uhr
2,640 Euro
+0,140
+5,60 %
+5,60 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,460 | 2,540 | 23.12. | |
| 2,440 | 2,560 | 23.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ANIXA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 22.11. | Anixa rises as board approves Bitcoin as a treasury reserve asset | 3 | Seeking Alpha | ||
| 22.11. | Anixa Biosciences diversifiziert mit Bitcoin-Investment | 4 | Investing.com Deutsch | ||
| 22.11. | Anixa Biosciences diversifies with Bitcoin investment | 2 | Investing.com | ||
| 18.11. | Anixa Hikes on Tests | 2 | Baystreet.ca | ||
| 18.11. | Anixa Biosciences, Inc.: Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial | 124 | PR Newswire | Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose
SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences... ► Artikel lesen | |
| 08.11. | Anixa reports progress in breast cancer vaccine trial | 1 | Investing.com | ||
| 08.11. | Anixa verzeichnet Fortschritte bei Brustkrebs-Impfstoff-Studie | 1 | Investing.com Deutsch | ||
| 08.11. | Anixa Biosciences, Inc.: Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual ... | 127 | PR Newswire | Data continues positive trend as additional patients are enrolled in 3 cohorts
Vaccine was safe and well tolerated by participants in all 3 cohorts
Protocol... ► Artikel lesen | |
| 08.11. | Anixa Biosciences Inc - 8-K, Current Report | - | SEC Filings | ||
| 15.10. | Anixa Biosciences, Inc.: Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial | 119 | PR Newswire | Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif., Oct. 15, 2024 /PRNewswire/... ► Artikel lesen | |
| 30.09. | Anixa strebt Genehmigung für wiederholte CAR-T-Dosen in Eierstockkrebs-Studie an | - | Investing.com Deutsch | ||
| 24.09. | Anixa Biosciences, Inc.: Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine | 451 | PR Newswire | Announces focus on therapeutic approach; resulting in a faster and more cost-effective path to approval
SAN JOSE, Calif., Sept. 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the... ► Artikel lesen | |
| 06.09. | Anixa Biosciences Inc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 23.07. | Anixa Biosciences, Inc.: Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy | 354 | PR Newswire | IND follows encouraging findings of necrosis, inflammation and T cell infiltration in tumor biopsy of patient in lowest dose cohort
SAN JOSE, Calif., July 23, 2024 /PRNewswire/ -- Anixa Biosciences... ► Artikel lesen | |
| 23.07. | EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy | 1 | Benzinga.com | ||
| 17.07. | Anixa Biosciences, Inc.: Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology | 125 | PR Newswire | SAN JOSE, Calif., July 17, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today... ► Artikel lesen | |
| 15.07. | Anixa Biosciences authorizes $5M share buyback program | 1 | Seeking Alpha | ||
| 15.07. | EXCLUSIVE: Anixa Biosciences Finds Stock Undervalued, Launches $5M Stock Buyback Program | 1 | Benzinga.com | ||
| 24.06. | Anixa Biosciences, Inc.: Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial | 141 | PR Newswire | This patient is expected to be the final patient in the second dosage cohort of the trial
SAN JOSE, Calif., June 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:... ► Artikel lesen | |
| 21.05. | Anixa Biosciences, Inc.: Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial | 556 | PR Newswire | Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumors
SAN JOSE, Calif., May 21, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the... ► Artikel lesen |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HUGO BOSS | 44,260 | +1,58 % | JPMORGAN stuft Hugo Boss auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Hugo Boss von 42 auf 44 Euro angehoben, aber die Einstufung auf "Neutral" belassen. Analystin Olivia Townsend passte ihre Schätzungen... ► Artikel lesen | |
| BIJOU BRIGITTE | 33,800 | -1,31 % | EQS-CMS: Bijou Brigitte modische Accessoires AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Bijou Brigitte modische Accessoires AG
/ Wöchentliche Meldung Aktienrückkauf
Bijou Brigitte modische Accessoires AG: Veröffentlichung einer... ► Artikel lesen |
ANIXA BIOSCIENCES INC gehört der Branche Bekleidung/Textil an. Mit einer aktuellen Kursveränderung von +0,140 (+5,60 %) liegt der Kurs bei 2,640 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANIXA BIOSCIENCES INC finden Sie auf Wallstreet Online.
